07:52 AM EST, 02/07/2025 (MT Newswires) -- Eli Lilly ( LLY ) said Friday that data from its VIVID-2 open-label extension study showed bowel disease drug Omvoh, mirikizumab-mrkz, provided long-term clinical remission and endoscopic response to patients with moderately to severely active Crohn's disease as well as for those with prior biologic failure.

Eli Lilly ( LLY ) said after two years of treatment, 92.9% of patients in clinical remission at one year remained in remission, while 87.6% maintained endoscopic response with visible healing of the intestinal lining. Of the patients in endoscopic remission at one year of treatment, 78.6% sustained endoscopic remission at two years.

According to the data, 60.8% of patients not in clinical remission at one year achieved remission in the second year. Of those patients not in endoscopic remission at one year, 35.4% gained remission in the second year, the company said.

Eli Lilly ( LLY ) said 6.8% of patients with endoscopic response at one year reported a serious adverse event, while 0.8% decided to end the treatment due to an adverse event.

The results will be presented at the Crohn's and Colitis Congress from Feb. 6 to Feb. 8.